^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Undisclosed αCD27 mAb

i
Other names: Undisclosed αCD27 mAb, anti-CD27 agonist
Associations
Trials
Company:
Grifols, Kineta
Drug class:
CD27 agonist
Associations
Trials
2years
CD27 an emerging immuno-oncology target at the cross-roads of innate and adaptive anti-tumor immune responses (SITC 2022)
Previous studies have demonstrated tumor growth inhibition with anti-CD27 agonistic monoclonal antibodies in different mice models for solid and hematological tumors...Preliminary experiments performed in human CD27 KI mice have demonstrated a long half-life of our antibody at different concentrations. Conclusions Epitope characterization, NHP pharmacokinetic analysis and additional in vivo studies of our lead anti-CD27 antibody in different tumor models use as a single agent and in combination with different check-point inhibitors are on-going.
IO biomarker
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CD70 (CD70 Molecule) • CD4 (CD4 Molecule) • CD69 (CD69 Molecule) • CD27 (CD27 Molecule)
|
CD8 expression • CD4 expression
|
Undisclosed αCD27 mAb